Biomea Fusion Inc
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Biomea Fusion Inc
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
/ 
Frequently asked questions
To buy Biomea Fusion Inc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Biomea Fusion Inc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Biomea Fusion Inc is BMEA:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Biomea Fusion Inc has its primary listing on NASDAQ. You can trade Biomea Fusion Inc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Biomea Fusion Inc is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Biomea Fusion Inc as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Biomea Fusion Inc.